33 Cipla, Lilly, GSK, Novartis Drugs Can Stay On India Market, DCGI Says
This article was originally published in PharmAsia News
Executive Summary
A total of 33 drugs from Cipla, Eli Lilly, GlaxoSmithKline and Novartis were given a pass by Indian drug authorities and allowed to remain on the market even though no local clinical trials were conducted.